BridgeBio Oncology Therapeutics Inc. (BBOT) Fundamental Analysis: Bull vs. Bear Case

BBOT

BridgeBio Oncology Therapeutics Inc.

Fundamental data last updated:September 27, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

VALUATION

P/E

-4.59

Market Cap ($M USD)

$708.15M

Forward P/E

-6.00

PEG

-0.26

PRICE TO SALES

0.00 PRICE TO BOOK

1.90 EV / EBITDA

-3.91

5-Year Average P/E

Free Cash Flow Yield

-24.42%

DCF Value

$11.88

Graham Number

N/A

Price to FCF

-4.09

EV to FCF

-3.81

Earnings Yield

-21.78%

FCF Yield

-24.42%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.93

Next Year EPS Growth Estimate

-$1.47

Next Year Revenue Growth Estimate

$107.65M

Return on Equity (ROE)

-61.49%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.01 Piotroski F-Score

1 Altman Z-Score

6.84 Return on Invested Capital (ROIC)

-45.10%

Current Ratio

6.16 Quick Ratio

6.16 Net Debt to EBITDA

0.30 Interest Coverage

0.00 Gross Profit margin

0.00%

FCF PER SHARE

$-2.16

REVENUE PER SHARE

$0.00

Gainseekers Quantitative Analysis

Summary

BBOT BridgeBio Oncology Therapeutics Inc. presents a perplexing valuation landscape. Recent pricing indicated it traded below its DCF value, suggesting potential undervaluation. However, the negative Forward P/E and Earnings Yield highlight significant profitability challenges. The Altman Z-score of 8.73 suggests financial stability, yet the market seems skeptical of its growth prospects. This dichotomy between safety and growth potential leaves investors questioning the true value proposition.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, BBOT is inherently positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's rapid tech evolution could enhance BBOT's research capabilities. However, the company's current financial metrics do not yet reflect a robust adaptation to these shifts.

The Bull Case

For the value-driven investor, BBOT's low Debt/Equity ratio and high Current Ratio signal a fortress-like balance sheet. Despite a negative ROIC and FCF Yield, the company's strong liquidity suggests resilience. The Piotroski F-Score of 2 may seem weak, but the potential for massive sales growth next year could indicate untapped pricing power. This setup might attract those betting on a turnaround story.

The Bear Case

BBOT's structural weaknesses are glaring. The negative Price to FCF and Earnings Yield underscore a troubling cash flow situation. With an EPS of -$4.30 and no gross profit margin, profitability remains elusive. Trading significantly below its 50-Day and 200-Day SMAs, the stock's technical position is precarious, raising concerns about its ability to rebound without substantial operational improvements.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$22.00

Institutional Ownership %

1-Year Beta

0.22 Insider Buying % (6 Mo)

Distance to 52-Week High

68.21%

Distance to 52-Week Low

14.03%

EARNINGS SURPRISE %

-2.76%

50-DAY SMA

$8.71

200-DAY SMA

$10.70

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.